C4 Therapeutics Announces First Patient Dosed in Phase III Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC^™ Degrader, in BRAF V600 Mutant Solid Tumors

C4 Therapeutics, Inc. announced the first patient had been dosed in its Phase I/II clinical trial of CFT1946, an orally bioavailable mutant-selective BiDAC™ degrader for the treatment of BRAF V600 mutant solid tumors.